Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy

Final draft guidance

Final draft guidance (PDF 253 KB)

Committee papers (PDF 6.19 MB)

Public committee slides (PDF 989 KB)

Committee meeting: 1

Final scope (PDF 203 KB)

Final stakeholder list (PDF 191 KB)

Draft scope and provisional stakeholder list comments table (post-referral) (PDF 401 KB)

Supporting documentation - draft scope (PDF 215 KB)

Final appraisal document - TA598 (PDF 264 KB)

Committee papers - TA598 (PDF 8.7 MB)

Public committee slides - TA598 (PDF 544 KB)

Managed access agreement - TA598 (PDF 365 KB)

Equality impact assessment - TA598 (PDF 140 KB)

Final scope - TA598 (PDF 247 KB)

Final stakeholder list - TA598 (PDF 257 KB)

Equality impact assessment (Scoping) - TA598 (PDF 175 KB)